Pharmaceutical compounds
US10647704B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2017 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Oct 18, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.